HomepageATYR • NASDAQ
add
aTyr Pharma Inc
$Â 5,33
Na sluitingstijd:(0,19%)-0,0100
$Â 5,32
Gesloten: 10 jul, 18:07:55 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 5,53
Dag-range
$Â 5,20 - $Â 5,55
Jaar-range
$Â 1,58 - $Â 5,98
Beurswaarde
474,39Â mln. USD
Gem. volume
3,45Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 3,96Â mln. | 12,89% |
Netto inkomsten | -14,88Â mln. | 3,94% |
Netto winstmarge | — | — |
Winst per aandeel | -0,17 | 26,09% |
EBITDA | -15,61Â mln. | 5,18% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 76,35Â mln. | -9,64% |
Totale activa | 97,24Â mln. | -14,13% |
Totale passiva | 22,38Â mln. | -22,73% |
Totaal aandelenvermogen | 74,86 mln. | — |
Uitstaande aandelen | 89,00 mln. | — |
Koers-boekwaardeverhouding | 6,58 | — |
Rendement op activa | -40,64% | — |
Rendement op kapitaal | -46,13% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -14,88Â mln. | 3,94% |
Operationele kasstroom | -15,42Â mln. | 31,10% |
Kasstroom uit beleggingen | -4,42Â mln. | -225,96% |
Kasstroom uit financiering | 18,63Â mln. | 140,98% |
Nettomutatie in liquide middelen | -1,21Â mln. | 92,43% |
Vrije kasstroom | -9,71Â mln. | 41,99% |
Over
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Opgericht
1 jan 2005
Website
Werknemers
61